Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys

Pharmaceutical Research

Volumn 17, Issue 12, 2000, Pages 1503-1510

  Drolet, D W ^a   Nelson, J ^b   Tucker, C E ^a   Zack, P M ^a   Nixon, K ^b   Bolin, R ^a   Judkins, M B ^b   Farmer, J A ^b   Wolf, J L ^a   Gill, S C ^a   Bendele, R A ^a  

^a GILEAD SCIENCES   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

SELEX; VEGF; VPF

Indexed keywords

PEGAPTANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VITREOUS BODY;

ANIMALS; BINDING, COMPETITIVE; BLOOD PRESSURE; BODY WEIGHT; EATING; ELECTRORETINOGRAPHY; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS; LYMPHOKINES; MACACA MULATTA; MALE; OLIGONUCLEOTIDES; ORGAN SIZE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 0034466813     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007657109012     Document Type: Article

References (24)

1. 165)
2. Diversity of oligonucleotide functions
3. Oligonucleotide libraries - Variatio delectat
4. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor
5. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes
6. Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity
7. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor
8. Liposome-anchored vascular endothelial growth factor aptamers
9. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution
10. 165-mediated cellular responses in vitro
11. In vivo antitumor efficacy of a VEGF-specific antagonist aptamer in a human rhabdomyosarcoma nude mouse xenograft model
12. The five year incidence and progression of age-related maculopathy
13. Age-related macular degeneration: Genetics and implications for detection and treatment
14. Angiogenesis inhibition in age-related macular degeneration
15. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
16. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
17. Increased expression of angiogenic growth factors in age-related maculopathy
18. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation
19. 125Ilabeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
20. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys
21. Purification of a highly modified RNA-aptamer, effect of complete denaturation during chromatography on product recovery and specific activity
22. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
23. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit
24. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy